Lepu Biopharma Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004SM4
HKD
4.58
0.1 (2.23%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
SciClone Pharmaceuticals (Holdings) Ltd.
Beijing Tong Ren Tang Chinese Medicine Co., Ltd.
Livzon Pharmaceutical Group, Inc.
Luye Pharma Group Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shandong Boan Biotechnology Co., Ltd.
RemeGen Co., Ltd.
Everest Medicines Ltd.
InnoCare Pharma Ltd.
Lepu Biopharma Co., Ltd.

Why is Lepu Biopharma Co., Ltd. ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
  • Poor long term growth as Net Sales has grown by an annual rate of 6.34% and Operating profit at 12.64% over the last 5 years
  • The company is Net-Debt Free
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 6.51%, its profits have risen by 26.6%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lepu Biopharma Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Lepu Biopharma Co., Ltd.
6.51%
0.07
68.60%
Hang Seng Hong Kong
8.76%
0.45
19.63%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
6.34%
EBIT Growth (5y)
12.64%
EBIT to Interest (avg)
-2.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.68
EV to EBIT
-4058.64
EV to EBITDA
-4393.51
EV to Capital Employed
7.42
EV to Sales
9131.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.18%
ROE (Latest)
-0.20%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
ROCE(HY)

Highest at 24.89%

NET SALES(Q)

Highest at HKD 513.36 MM

RAW MATERIAL COST(Y)

Fallen by -2,416.23% (YoY

CASH AND EQV(HY)

Highest at HKD 1,067.88 MM

DEBT-EQUITY RATIO (HY)

Lowest at 7.16 %

PRE-TAX PROFIT(Q)

At HKD -46.57 MM has Grown at 80.75%

NET PROFIT(Q)

Highest at HKD 256.08 MM

EPS(Q)

Highest at HKD 0.14

-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 3.87 times

Here's what is working for Lepu Biopharma Co., Ltd.

Net Sales
At HKD 513.36 MM has Grown at 101.79%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely positive

Net Sales (HKD MM)

Net Sales
Highest at HKD 513.36 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (HKD MM)

Net Profit
At HKD 256.08 MM has Grown at 205.31%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (HKD MM)

Pre-Tax Profit
At HKD -46.57 MM has Grown at 80.75%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit
Highest at HKD 256.08 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS
Highest at HKD 0.14
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Cash and Eqv
Highest at HKD 1,067.88 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at 7.16 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -2,416.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Lepu Biopharma Co., Ltd.

Inventory Turnover Ratio
Lowest at 3.87 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio